AI assistant
PTC THERAPEUTICS, INC. — Director's Dealing 2025
May 19, 2025
31046_dirs_2025-05-19_5fa3474f-474f-4be7-bed1-63e8616119fd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2025-05-15
Reporting Person: Boulding Mark Elliott (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-15 | Common Stock | M | 1929 | $25.69 | Acquired | 105830 | Direct |
| 2025-05-15 | Common Stock | S | 1929 | $46.18 | Disposed | 103901 | Direct |
| 2025-05-16 | Common Stock | M | 883 | $25.69 | Acquired | 104784 | Direct |
| 2025-05-16 | Common Stock | S | 883 | $46.02 | Disposed | 103901 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-15 | Stock Option (Right to Buy) | $25.69 | M | 1929 | Disposed | 2034-02-14 | Common Stock (1929) | Direct |
| 2025-05-16 | Stock Option (Right to Buy) | $25.69 | M | 883 | Disposed | 2034-02-14 | Common Stock (883) | Direct |
Footnotes
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.61 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.19 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.